← Zai Lab Limited (ZLAB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Zai Lab Limited (ZLAB)
Pharmaceutical Preparations · market cap $3.0B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
10
programs
Upcoming events
4
next 90d+
Dossier
Ready
cached
Zai Lab (ZLAB) is a ~$1.8B market cap biopharma with 1,869 employees, operating primarily in China and globally, with a diversified pipeline spanning oncology, infectious disease, immunology, and rare disease. The company is loss-making but revenue is accelerating ($460M in 2025 vs. $144M in 2021), and the highest-importance near-term catalyst is a Phase 3 readout for ZL-1109 (VRDN-003) in Thyroid Eye Disease expected around March 2027. Cash of $651M provides an estimated 164-month runway, offering meaningful financial stability.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
- 2027-03-14 (est.)Phase 3 · ZL-1109 (VRDN-003)imp 9/10
- 2027-08-15 (est.)Phase 3 · ZL-1310imp 9/10
- 2027-08-15 (est.)Phase 2 · ZL-1310imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Investigator's Choice of Therapy | Phase 3 | Small-cell Lung Cancer |
| Brivanib 800 mg, QD | Phase 2 | Hepatocellular Carcinoma (HCC) |
| ZL-1102 1% w/w gel BID for 16 weeks | Phase 2 | Plaque Psoriasis |
| Ripretinib | Phase 2 | Gastrointestinal Stromal Tumor(GIST) |
| Omadacycline | Phase 3 | Community-acquired Bacterial Pneumonia |
| ZL-1109 (VRDN-003) | Phase 3 | Thyroid Eye Disease (TED) |
| ZL-3101 | Phase 2 | Eczema |
| DCC-2618 | Phase 2 | Gastrointestinal Stromal Tumors |
| ZL-2306(Niraparib） | Phase 2 | Ovarian Cancer |
| ZL-1310 | Phase 3 | Solid Tumors |
Price & technical context
3-month
+33.4%
6-month
+25.4%
12-month
-24.8%
52-wk range
$16.30–$34.44
vs 50-day MA
+5.7%
vs 200-day MA
+25.3%
Realized vol
49.1%
Max drawdown
-62.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ZLAB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 10 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.